Leukemia growing as tumors in gastrointestinal organs is an under-investigated cause of treatment failure and death. These present with symptoms often mistaken for common toxicities but may grow large before symptoms. To synthesize experience available only in case reports, 378 were analyzed. Invasive and metastatic behavior typical of solid GI tumors was revealed even when marrow was uninvolved. Within 3 months of diagnosis, 33% had died, 47% within 1 year. Survivals of 4 to 18 years after involvement suggest cure is possible. Evidence is presented that combined local and systemic therapy has successfully treated GI leukemic tumors when identified early.
| INTRODUCTION
The persistently high rate of relapse and primary refractory disease remain obstacles to curing acute leukemia. One means of resistance and relapse, long recognized but still under-investigated, is the formation of leukemic cells into tumors that occur in some patients. These tumors are variously called granulocytic sarcoma, chloroma, and extramedullary myeloid tumor, though they occur in lymphoblastic leukemia as well. Leukemia cells that adopt solid tumor phenotype invade tissue, metastasize, and lead to death, even when marrow is in remission. This tumor behavior was recognized by pathologists a century ago as the "more malignant form of leukemia" 1 .
Extramedullary tumors can occur in anybody organ, but in the 60 years that marrow-directed chemotherapy has been available, The last autopsy studies of leukemia patients were published in the early 1960s, prior to the chemotherapy era, when survival was measured in months. They found the incidence of gross GI leukemic lesions to be 18%-21%, increasing to over 50% if microscopic involvement was included. 4, 5 Without autopsies, scans, and prospective studies, the true current incidence cannot be known. Without documentation that there is no occult extramedullary leukemia involvement before initiation of therapies, including transplant, the chance of success may be diminished and the reason unknown.
There is a critical need for comprehensive knowledge of the presentation and behavior of leukemic tumors if curative therapy is to be 3 | RESULTS
| Presentation of leukemic GI tumors
There are 378 cases of leukemic GI tumors in patients with acute myeloid and lymphoid leukemias (AML and ALL), chronic myeloid leukemia (CML), and myelodysplaia (MDS) or myeloproliferative neoplasia (MPN) included in this analysis. Eighty-percent were published since 2000. Only 40% of cases were published in hematology or oncology journals, so most lack details typical of leukemia case descriptions such as recognized prognostic factors. However, every FAB leukemia subtype and both normal and abnormal karyotypes are represented. The ages and genders of patients and the phases of leukemia in which tumors were recognized are shown in Table 1 . Table 2 enumerates the principal organs involved.
The majority of reports (65%) concern people who presented to surgeons or internists with GI symptoms and no known history of leukemia. Of these, bone marrow did not show morphologic evidence of leukemia in 110 cases. Their GI tumors were all myeloid leukemia, confirmed by histology and markers. In the other 135 new patients, bone marrow was involved with AML, ALL, CML, MDS, or MPN.
Included in the total cases are 3 patients who had had prior organ transplants: of liver 6 or kidney. 7 Five cases had both solid cancer and myeloid leukemia ("collision tumors") in rectum, 8, 9 colon, 10, 11 or stomach. 12 In 5 cases, leukemic GI tumor was diagnosed only at autopsy. [13] [14] [15] [16] In 133 reports, GI tumor was first recognized as a sign of relapse after chemotherapy or stem cell transplants. In at least 8 of these cases, there had been prior extramedullary leukemia in other organs. ; perforation has occurred.
| Growth characteristics of GI tumors
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Pancreatic tumors typically present with jaundice and pain.
Masses as large 10 cm have been seen. 21 Pancreatic involvement is frequently accompanied by kidney tumors. 22 Confusion of symptoms with solid cancer, pancreatitis, 23 or graft-vs-host disease, 24, 25 contribute to delay in diagnosis, specifically noted in at least 25% of reports.
Gallbladder and bile duct involvement present with symptoms typical of cholecystitis; radiology may suggest Klatskin tumors. 22 Appendix tumors present with pain and may grow as large as 8 cm 26 and extend into fat. Liver involvement may present with pain or symptoms of cholestasis and very high lactate dehydrogenase levels. Nodules or masses as large as 11 cm 27 have been reported, as well as sinusoidal infiltration and fulminant liver failure. 28, 29 Esophageal involvement presents as dysphagia and ulcers, which are often hemorrhagic.
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Mesentery and peritoneum involvement present as pain and diagnosis is often made on ascitic fluid. Masses of 10 cm were reported, 31, 32 as well as studding similar to peritoneal carcinomatosis and mesothelioma. 8 cases of small intestine tumor without surgery, 1 had no therapy and died, and 2 had radiation. One who had RT to a 6 × 8 cm duodenal tumor followed by chemotherapy was well at 3.5 years, 41 and the other had subsequent relapse in marrow and salvage chemotherapy achieved remission ongoing over 5 years. 42 Five cases received only chemotherapy, 4 were alive without relapse at 1, 6, 6, and 8 years. 37, 43, 44 Interestingly, 4 of the 5 reports noted that extensive chemotherapy courses were given; 1 patient also underwent transplant. 43 An additional 46 reported patients had tumors in GI organs other than small intestine without marrow leukemia, shown in One had hemicolectomy for perforated cecum whose pathology showed both adenocarcinoma and myeloid leukemia involvement. He did well for 3 years until a small bowel obstruction; its etiology was not ascertained before his death. 9 The other had a 6 cm. abdominal recurrence 7 months after pancreatic tumor resection and was well 14 years after radiation and chemotherapy. 51 Among 25 cases that were not given surgery, 7 died without therapy, and one, who had a prior renal transplant, achieved response by decrease of immunosuppression that was ongoing at 2 years. 7 Seventeen received only chemotherapy, with 7 responses reported. There were 4 responses of primary mesenteric involvement, ongoing at 1-3 years. 32, 33, 52, 53 There was also a 2+ year response to AML induction therapy for a stomach tumor. 54 Two responses of pancreas tumors to lengthy systemic treatment were documented by scans. One, confirmed to be isolated in pancreas and omentum by PET/CT, had response, confirmed by PET/CT, to 4 courses of AML therapy followed by transplant ongoing at 1.5+ years. 21 The other achieved complete response in tumor gradually during 5 cycles of chemotherapy, confirmed on CT, and continued well, without marrow leukemia, at 7 years. 75 An additional patient with small bowel tumor had relapse in both marrow and organ sites and was well 2 years after salvage chemotherapy and autologous transplant. 58 Of the 52 patients who did not undergo local treatment, 9 were reportedly surviving with response after chemotherapy alone for 2 to 10 years. 63, [76] [77] [78] [79] [80] [81] [82] [83] Three of the long survivors had also had stem cell transplants: one after pancreatic tumor, 77 one after duodenal tumor, 80 and one after retroperitoneal tumor that compressed duodenum. 63 The response of one was confirmed by negative PET/CT scans over 5 years. 63 The patient well over 10 years had relapsed after chemotherapy alone for stomach tumor in pancreas and marrow and long-term disease control was achieved after salvage therapy. 83 The single case treated with irradiation of colon tumor and chemotherapy was noteworthy because after death from aspergillus, autopsy showed no extramedullary tumor. well without obvious relapse at 4 and 6 years after tumors of appendix 87 and gallbladder. 74 Of 8 patients given only chemotherapy without surgery, 7 had no response and one was well 2 years after leukemic tumor in duodenum. 88 Among the 29 cases of post-stem cell transplant relapse in GI sites 1 month to 7 years after transplant, half were diagnosed 2 or more years after. Of reports that included marrow evaluations, 22 (79%) cases did not show marrow relapse, 4 showed morphologic relapse, and 2 showed molecular relapse. Extent of involvement was evaluated by body scans in 15 cases by PET, with or without CT, and in one by gallium. 89 Half of those scans showed evidence of only one involved area. Among other cases examined by regional radiology and ultrasounds, multi-site involvement was suggested in the majority. Graft-vshost disease had occurred in 12 of 13 cases where it was mentioned.
In one particularly interesting case, GVHD of bowel had been diagnosed on biopsy 5 months before death. At autopsy, myeloid tumor was found in intestine and other GI organs; marrow was not involved. 90 Of the 29 total GI relapses posttransplant, surgery was undertaken in only 8, with additional RT in 1, and 3 had postoperative chemotherapy. Five patients were treated with RT instead of surgery.
Four of the 6 who had combined therapy with survival detail, 3 relapsed in marrow, other sites, or both and one continued well at 23+ months after tumors in ileum. 100 None of the 8 patients treated with chemotherapy alone survived. One other patient, a 42-year old with stomach tumor but no marrow relapse ultimately did well after salvage therapy.
She had no surgery and was treated with donor lymphocyte infusions, and marrow showed 27% blasts 3 months after tumor diagnosis.
Salvage chemotherapy and further DLI infusions resulted in negative endoscopies and no other relapses for 10+ years. 91 
| Experience in acute megakaryocytic leukemia
There are 3 cases of young patients with GI involvement with acute megakaryocytic leukemia. One 2-year old with Down's syndrome had involvement of pancreas, gallbladder, liver, and ovary at initial marrow diagnosis. Complete remission was attained after 2 cycles of AML therapy and she was well at 6 months. 91 GI tumors were found after transplants in 2 others. In a 1-year old, liver nodules (the only site on PET/CT scan) were diagnosed 2 months posttransplant with marrow relapse soon thereafter and she died. 92 The other, age 18, was found to have stomach and thymus tumors 4 months after transplant. He was treated with a second transplant; meningeal relapse was found 9 months later, heralded by rise in peripheral blood WT1. Five months after local CNS therapy, WTI increased to 48 000 copies; marrow showed relapse that was refractory to chemotherapy. 93 
| Experience in CML
Of 22 cases of GI involvement in CML, 12 were reported at diagnosis or after treatment before tyrosine kinase inhibitors were available.
Among the 12, there are no documented survivals over 9 months.
Of 10 cases reported since TKI availability, 3 had GI involvement at CML diagnosis. One of the 3 had mesenteric involvement diagnosed on ascitic fluid, which cleared after 3 months of imatinib and he was well at 14 months. 94 One patient with myeloid colon polyp that presented with hematochezia received dasatinib after its removal and was well 5 years later. 95 The third had intestine involvement that responded to radiation followed by transplant, with imatinib and bosutinib maintenance, and was well over 10 years. 96 Seven patients had GI involvement after treatment of CML, 5 after drug therapy and 2 after transplants. Two had GI tumors diagnosed subsequent to treatment with imatinib, one as an obstructing small bowel tumor when myeloblastic CML was in cytogenetic remission; he died after progression to brain involvement. 97 In the other, a 5-cm pancreas tumor was found when marrow showed 30% myeloblasts. With dasatinib, molecular marrow response was obtained with partial response in pancreatic tumor, he was reported to be alive at 2 years. 98 Another patient developed multiple liver and gallbladder lesions after 2 years of dasatinib for myeloblastic CML. 99 Marrow remission was attained after transplant followed by relapse in chronic phase after 6 years. On dasatinib, he is well at 3 years. 99 Stomach tumors were found in 2 patients 4.5 months after transplants. One had undergone transplant after progression to blastic CML on imatinib. Posttransplant dasatinib for 6 months was followed by meningeal relapse. Molecular remission continued in marrow, and after craniospinal radiation and nilotinib, the patient was well at 8+ years. 100 In the other, after stomach nodules were diagnosed, immunosuppressive drugs were stopped and by 6 months, there was no evidence of tumor. He then received imatinib and was well at 5 years. 101 A case that illustrates difficulty in making a correct diagnosis is that of a 53 year old man with a 13-year history of Crohn's disease and a 2-year history of CML. He underwent an extensive proctocolectomy for severe colitis and had blastic transformation of marrow. Months later, re-evaluation of the surgical specimen revealed that what had appeared to be Crohn's disease was actually myeloblastic tumor. 102 
| Experience in MDS and MPN
There are 37 reports of cases of leukemic involvement in GI organs in patients deemed to have marrow evidence of MDS or MPN. A total of 11 patients were younger than 60. Eight cases had no prior history of hematologic disorder when involvement of a GI site was diagnosed as myeloid; in these cases, marrows were interpreted as chronic myelomonocytic leukemia or refractory anemia with excess blasts. The only 2 who survived 5 months were alive at 2 and 3 years, having undergone resections of small intestine tumor 103 or colonic mass that contained both AMML cells and colon cancer. 9 The other 29 cases were identified after treatment with various regimens. Seven had been treated for CMML for 6 to 24 months when leukemic tumors of esophagus, colon, or stomach were diagnosed. Only one survived 10 months.
Eighteen other patients had been treated for MDS or RAEB (blasts ranging from 7% to 32%) including 2 with transplants. 104, 105 In at least 11, marrows were considered to have transformed to AML. Four other cases had MPN transforming to AML, including one who had had essential thrombocytosis for 5 years 106 and one with myelofibrosis for 16 years. 107 Overall, surgery was performed in 6 cases, 1 of whom survived 15 months. 107 The median survival of all of the reported MDS/MPN cases was 3 months. nodules, and subsequent gallium scan showed pancreatic involvement. 108 Another had an unremarkable abdominal ultrasound, but abnormal uptake was found in kidney, liver, and pancreas on PET/CT. 109 The most commonly reported site was the pancreas in 10 patients, with simultaneous kidney involvement in 6. In only 1 case was the diagnosis confirmed by pancreas biopsy. 110 Surgery was undertaken in only 2 ALL cases, both with appendix involvement; after surgery, both obtained marrow remission with chemotherapy. All but one of the total cases was treated with chemotherapy; at least 11 patients were reported to achieve complete remissions of marrow and tumor. Of the 11, 3 were alive from 1 to 4+ years after pancreas tumors, 108,111,112 2 at 3 and 5 years after stomach tumors 113, 114 and a 6-year-old with bile duct involvement was alive at 1 year. 115 In 4 reports, involvement of intestine was first recognized in patients during induction therapies. Intussusception caused by tumor was found in 3 boys, ages 7 months to 14 years, between day 4 and 3 months of chemotherapy; all underwent surgery followed by chemotherapy. Two subsequently relapsed 116, 117 and one was alive at 1 year. 118 One 67-year-old experienced ileal perforations on day 39 of chemotherapy and died; diagnosis was made at autopsy. 119 
| ALL relapse in GI sites
Eighteen ALL cases were reported with GI tumors 6 to 10 years after chemotherapy. Multiple organ involvement was seen on regional scans in at least half. Only 7 had simultaneous marrow relapse; 2 with only 10% and 30% blasts. Two patients, ages 2 and 7, presented with intestinal perforations; both died without treatment. Autopsies showed no other extramedullary leukemia in one, 14 and extensive disease in the other. 15 In another case, autopsy revealed an unsuspected pancreatic nodule in a 19 year old with refractory ALL. 16 Only 8 patients underwent tumor excision, followed by chemotherapy in at least 6. Two continued free of disease at 4 and 7.5 years after appendectomy and ileal resection, respectively, and very extensive chemotherapy. 129, 130 Two of 4 treated with chemotherapy without surgery, 2 had noteworthy survival after late extramedullary relapses. One, originally diagnosed at age 3 1/2, relapsed 10 years later in stomach, colon, and testes with 30% marrow blasts. He was treated with a BFM protocol with resolution of tumors documented by PET/CT. Relapse in testis a year later, with 10%-15% marrow blasts, was treated with orchiectomy followed by transplant and he continued well 6 years later. 120 The other, a girl diagnosed at 8 years old, relapsed 3 years later in appendix, retroperitoneum, and ovaries, considered unresectable after biopsies. She received chemotherapy for almost 4 years without documentation of tumor response and died 52 months after extramedullary relapse, without ever having marrow relapse. All the other patients died within a year.
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Seventeen ALL cases relapsed in GI organs as late as 8 years 121 after transplants. The pancreas was the most commonly involved site, in at least 9 cases. Involvement of more than one GI site was seen by regional radiology or PET scans in the majority. [121] [122] [123] Only 3 had evidence of morphologic marrow relapse, one with only 10% blasts. 123 Surgery was performed in only 4 cases, and 4 received only chemotherapy. Although most patients died within a few months, there were 2 noteworthy responses. One, treated with radiation only to a pancreatic tumor, was well 55 months later. 124 The other had a scalp relapse 2 months posttransplant, and marrow showed 10% marrow blasts.
PET/CT showed an area of involvement around gallbladder and intestine and other soft tissue sites. All sites resolved on PET/CT in 2 months after treatment with vincristine, interferon, and G-CSF. A year later, isolated pericardial relapse was treated with the same regimen, and she continued well a year later. liver, and stomach. There is suggestive evidence from some cases that ALL tumors may be more sensitive to ALL drugs than AML tumors are to AML agents. Although optimal therapy cannot be determined from this observational study, two points are worth highlighting. The use of radiation is infrequently reported. Its efficacy in eradicating leukemic tumors has been known for decades 129 and is demonstrated in several GI cases. 41, 84, 124 It is noteworthy that lengthy duration of intensive chemotherapy appears to have prevented marrow relapse in several reports.
There are clues to possible involvement of extramedullary organs that may aid clinicians in making earlier diagnosis. They include unexplained increase in lactic dehydrogenase levels, a rise in markers of minimal residual disease in blood but not in marrow, such as WT1, 21, 93, 130 CBFβ-MYH11, 38, 131 and RUNX1/RUNX1T1 transcript 90 and higher percentage of blasts in blood than marrow. Low percentage of blasts in marrow may indicate tumor cell metastasis to marrow.
Leukemic blasts that had transformed in forming tumor and then invaded marrow may be resistant to agents developed to treat leukemic blasts in marrow. decreasing delay in diagnosis, and assuring complete eradication, will increase our ability to eradicate the total leukemic burden of more patients.
| CONCLUSION
